Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$0.86
-12.2%		$0.71
$0.55
▼
$1.69
$12.34M1.52423,770 shs1.17 million shs
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
$1.14
-4.2%		$1.12
$0.62
▼
$6.25
$7.85M1.9420.18 million shs248,896 shs
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
$0.72
+13.8%		$0.94
$0.59
▼
$19.21
$2.19M3.73984,938 shs3.80 million shs
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
$3.97
+2.8%		$2.98
$1.90
▼
$13.93
$8.84M2.173,878 shs23,919 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
+3.17%+46.05%+56.88%+5.32%-37.97%
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
-4.03%+6.25%+50.01%-47.35%-62.34%
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
-1.84%+5.95%-17.08%-73.75%-96.78%
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
+1.05%+14.88%+54.40%+25.32%+35.44%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$0.86
-12.2%		$0.71
$0.55
▼
$1.69
$12.34M1.52423,770 shs1.17 million shs
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
$1.14
-4.2%		$1.12
$0.62
▼
$6.25
$7.85M1.9420.18 million shs248,896 shs
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
$0.72
+13.8%		$0.94
$0.59
▼
$19.21
$2.19M3.73984,938 shs3.80 million shs
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
$3.97
+2.8%		$2.98
$1.90
▼
$13.93
$8.84M2.173,878 shs23,919 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
+3.17%+46.05%+56.88%+5.32%-37.97%
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
-4.03%+6.25%+50.01%-47.35%-62.34%
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
-1.84%+5.95%-17.08%-73.75%-96.78%
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
+1.05%+14.88%+54.40%+25.32%+35.44%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
2.40
Hold$3.07256.55% Upside
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
2.00
HoldN/AN/A
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
1.50
Reduce$150.0020,820.50% Upside
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest GOVX, CELZ, XBIO, and APRE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2026
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/13/2026
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/13/2026
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$3.00
7/31/2026
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/17/2026
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 8/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$290K37.34N/AN/A$3.06 per share0.28
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
$10K751.26N/AN/A$1.32 per share0.86
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
$2.49M1.00N/AN/A$0.51 per share1.41
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
$2.98M3.05N/AN/A$2.65 per share1.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$12.60M-$1.08N/AN/AN/A-4,405.59%-47.60%-40.97%11/11/2026 (Estimated)
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
-$5.99M-$2.07N/AN/AN/AN/A-86.52%-81.96%11/6/2026 (Estimated)
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
-$21.47M-$11.34N/AN/AN/AN/A-743.64%-394.74%11/12/2026 (Estimated)
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
-$2.68M-$1.16N/AN/AN/A-75.90%-40.62%-34.97%11/6/2026 (Estimated)

Latest GOVX, CELZ, XBIO, and APRE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$0.1775-$0.07+$0.1075-$0.07$0.25 millionN/A
8/7/2026Q2 2026
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
-$0.39-$0.41-$0.02-$0.41N/AN/A
8/6/2026Q2 2026
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
N/A-$0.41N/A-$0.41N/A$0.66 million
7/27/2026Q2 2026
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
-$2.16-$0.97+$1.19-$0.97N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/AN/AN/AN/AN/A
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
N/AN/AN/AN/AN/A
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
N/AN/AN/AN/AN/A
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/A
13.56
13.56
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
N/A
12.90
12.90
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
N/A
1.54
1.54
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
N/A
7.43
7.43

Institutional Ownership

CompanyInstitutional Ownership
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
34.19%
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
1.42%
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
6.09%
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
15.12%

Insider Ownership

CompanyInsider Ownership
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
10.49%
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
1.00%
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
0.69%
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
712.59 million11.27 millionNo Data
Creative Medical Technology Holdings, Inc. stock logo
CELZ
Creative Medical Technology
56.59 million6.53 millionNot Optionable
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
103.47 million3.45 millionNot Optionable
Xenetic Biosciences, Inc. stock logo
XBIO
Xenetic Biosciences
42.29 million2.12 millionNot Optionable

Recent News About These Companies

Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Large Increase in Short Interest
August 27 at 3:54 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30986685
Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform
August 7, 2026  |  accessnewswire.comA
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of ...
June 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/xenetic-biosciences-inc-announces-collaboration-124000825.html
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma
June 4, 2026  |  accessnewswire.comA
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
June 1, 2026  |  accessnewswire.comA
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
May 13, 2026  |  accessnewswire.comA
Xenetic Biosciences: Q1 Earnings Snapshot
May 12, 2026  |  wtop.comW
Xenetic Biosciences Grants Equity Award to Interim CEO
April 27, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/XBIO/pressreleases/1520659/xenetic-biosciences-grants-equity-award-to-interim-ceo/
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
April 22, 2026  |  accessnewswire.comA
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results
March 13, 2026  |  accessnewswire.comA
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting
December 11, 2025  |  accessnewswire.comA
Xenetic extends R&D collaboration with The Scripps Research Institute
November 19, 2025  |  msn.comhttps://www.msn.com/en-us/technology/biotechnology/xenetic-extends-r-d-collaboration-with-the-scripps-research-institute/ar-AA1QKDxC
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform
November 19, 2025  |  accessnewswire.comA
Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results
November 13, 2025  |  accessnewswire.comA
Xenetic Biosciences Announces Public Offering Pricing
October 14, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/xenetic-biosciences-announces-public-offering-pricing/ar-AA1Ossgk
Xenetic 735,000 share Spot Secondary priced at $6.12
October 10, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/xenetic-735000-share-spot-secondary-priced-at-612/ar-AA1Oeziy
Micron, Galecto And Xenetic Lead This Week's Benzinga Stock Ranking Surges
October 10, 2025  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/25/10/48161813/micron-galecto-and-xenetic-lead-this-weeks-benzinga-stock-ranking-surges
Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock
October 10, 2025  |  accessnewswire.comA
Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results
August 13, 2025  |  accessnewswire.comA
Xenetic Biosciences Reports Improved Financial Performance
August 13, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/xenetic-biosciences-reports-improved-financial-performance/ar-AA1KqObx

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aprea Therapeutics stock logo

Aprea Therapeutics NASDAQ:APRE

$0.86 -0.12 (-12.23%)
Closing price 03:59 PM Eastern
Extended Trading
$0.87 +0.01 (+1.27%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Creative Medical Technology stock logo

Creative Medical Technology NASDAQ:CELZ

$1.14 -0.05 (-4.20%)
Closing price 04:00 PM Eastern
Extended Trading
$1.14 0.00 (-0.44%)
As of 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

GeoVax Labs stock logo

GeoVax Labs NASDAQ:GOVX

$0.72 +0.09 (+13.79%)
Closing price 04:00 PM Eastern
Extended Trading
$0.73 +0.01 (+1.81%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

Xenetic Biosciences stock logo

Xenetic Biosciences NASDAQ:XBIO

$3.97 +0.11 (+2.85%)
Closing price 04:00 PM Eastern
Extended Trading
$3.92 -0.05 (-1.13%)
As of 06:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas